drugset / Trial / NCT02638129
Naltrexone/Bupropion Cardiovascular Outcomes Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo and rule out excess risk of major adverse cardiovascular events (MACE) when given in combination with standard of care in overweight and obese participants with documented history of CV disease.
Timeline
- Start
- 2016-01
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | 90 mg | — |
| Subject | Naltrexone | Small molecule | 8 mg | — |